CrushSCI.com
150.1Average days
91Median days
29Fastest days
420Longest days
252025 publications

Paper Review Records

All Paper Review Records

14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

66 days

Acute management of adult MOG antibody–associated disease: therapeutic choices and clinical outcomes

Authors
Edgar Carnero Contentti; Eoin P. Flanagan; Ethel CiampiShow moreShow less
Affiliations
1. Hospital Alemán; 2. INECO Neurociencias Oroño; 3. Mayo Clinic College of Medicine; 4. Pontificia Universidad Católica de Chile; 5. Red de Salud UC CHRISTUS; 6. Hospital Dr Sotero del RioShow moreShow less
Source PDF DOI Publisher page
48 days

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies

Authors
Lanfranco Pellesi; Damiana Scuteri; Andrea Burgalassi; Alberto Chiarugi; Paolo MartellettiShow moreShow less
Affiliations
1. University of Southern Denmark; 2. University “Magna Graecia” of Catanzaro; 3. Careggi University Hospital; 4. Unitelma Sapienza University of RomeShow moreShow less
Source PDF DOI Publisher page
95 days

Emerging small molecules for ulcerative colitis: clinical advancements and trial insights

Authors
Cristina Lanzotti; Fabrizio Fanizzi; Ferdinando D’Amico; Alessandra Zilli; Federica Furfaro; Mariangela Allocca; Virginia Solitano; Clelia Cicerone; Sara Massironi; Tommaso Lorenzo Parigi; Laurent Peyrin-Biroulet; Silvio DaneseShow moreShow less
Affiliations
1. IRCCS San Raffaele Hospital; 2. Vita-Salute San Raffaele University; 3. Istituti Ospedalieri Bergamaschi; 4. INFINY Institute, CHRU NancyShow moreShow less
Source PDF DOI Publisher page
135 days

Emerging claudin-18.2 antagonists in the treatment of biliary tract cancer

Authors
Daniel Neureiter; Dino Bekric; Christian Mayr; Tobias Kiesslich; Matthias OckerShow moreShow less
Affiliations
1. Paracelsus Medical University/University Hospital Salzburg (SALK); 2. Cancer Cluster Salzburg; 3. Paracelsus Medical University; 4. University Clinics Salzburg, Paracelsus Medical University; 5. Campus Charité Mitte, Charité University Medicine Berlin; 6. EO Translational Insights Consulting GmbH; 7. Tacalyx GmbHShow moreShow less
Source PDF DOI Publisher page
420 days

Emerging pharmacotherapies in Gaucher disease

Authors
Gregory M. PastoresShow moreShow less
Affiliations
1. University College DublinShow moreShow less
Source PDF DOI Publisher page
74 days

Phase II and III trials in systemic sclerosis: from recent FDA approvals to emerging applications of cellular therapies

Authors
Alain Lescoat; Eisha Naveed; Dinesh KhannaShow moreShow less
Affiliations
1. University of Rennes CHU Rennes, Inserm, EHESP; 2. University of Michigan Scleroderma ProgramShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.